Outcomes after radiotherapy and brachytherapy
Poster Session 51

Sunday 17 March
15:45 - 17:15

Location: Green Area, Room 2
Chairs: A. Bossi, Villejuif (FR)
G. Morgia, Catania (IT)
C. Surcel, Bucharest (RO)

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

717

Dose-effect relationship for 1-year incontinence after post-prostatectomy intensity-modulated radiotherapy (MRT)

By: Gabriele P. ¹, Cante D. ², Sanguineti G. ³, Munoz F. ⁴, Avuzzi B. ⁵, Garibaldi E. ¹, Noris Chiorda B. ⁵, Villa E. ⁶, Saracino B. ³, Girelli G. ⁷, Waskiewicz J.M. ⁸, Magli A. ⁹, Valdagni R. ¹⁰, Badenchini F. ¹¹, Di Muzio N. ¹², Rancati T. ¹¹, Fiorino C. ¹³, Tutolo M. ¹⁴, Gandaglia G. ¹⁴, Fossati N. ¹⁴, Briganti A. ¹⁴, Montorsi F. ¹⁴, Cozzarini C. ¹²

¹Istituto di Candiolo- Fondazione del Piemonte per l’Oncologia IRCCS, Dept. of Radiotherapy, Candiolo, Italy,
²Ospedale di Ivrea, A.S.L. TO4, Dept. of Radiotherapy, Ivrea, Italy,
³Istituto Nazionale dei Tumori Regina Elena, Dept. of Radiotherapy, Rome, Italy,
⁴Ospedale Regionale U.Parini-AUSL Valle d’Aosta, Dept. of Radiotherapy, Aosta, Italy,
⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy,
⁶Cliniche Gavazzeni-Humanitas GAV, Dept. of Radiotherapy, Bergamo, Italy,
⁷Ospedale degli Infermi, Dept. of Radiotherapy, Biella, Italy,
⁸Comprensorio Sanitario di Bolzano, Dept. of Radiotherapy, Bolzano, Italy,
⁹Azienda Ospedaliero Universitaria S. Maria della Misericordia, Dept. of Radiotherapy, Udine, Italy,
¹⁰University of Milan, Department of Oncology and Hemato-oncology - Fondazione IRCCS Istituto Nazionale dei Tumori, Prostate Cancer Program - Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy,
¹¹Programma Prostata, Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy,
¹²IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy,
¹³IRCCS Ospedale San Raffaele, Dept. of Medical Physics, Milan, Italy,
¹⁴IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

715

Hyprofractionated vs conventionally fractionated radiotherapy for prostate cancer: 7-year outcome from the Dutch HYPRO trial

By: Wortel R.C. ¹, De Vries K. ², Pos F.J. ³, Oomen-De Hoop E. ², Heemsbergen W.D. ², Incrocci L. ²

¹UMC Utrecht, Dept. of Urology, Utrecht, The Netherlands,
²Erasmus MC, Dept. of Radiation Oncology, Rotterdam, The Netherlands,
³Netherlands Cancer Institute, Dept. of
Aims and objectives of this presentation

Comparison of self-reported acute urinary incontinence in patients treated with adjuvant or salvage post-prostatectomy intensity modulated-radiotherapy (IMRT)

By: Munoz F.¹, Cante D.², Garibaldi E.³, Sanguineti G.⁴, Faiella A.⁴, Avuzzi B.⁵, Noris Chiorda B.⁵, Vavassori V.⁶, Villa E.⁶, Girelli G.⁷, Waskiewicz J.M.⁸, Magli A.⁹, Badenchini F.⁵, Bianconi C.¹⁰, Valdagni R.⁵, Di Muzio N.¹⁰, Rancati T.⁵, Fiorino C.¹⁰, Tutolo M.¹¹, Fossati N.¹¹, Gandaglia G.¹¹, Briganti A.¹¹, Montorsi F.¹¹, Cozzarini C.¹⁰

¹Ospedale Regionale U.Parini, AUSL Valle d’Aosta, Dept. of Radiotherapy, Aosta, Italy, ²Ospedale di Ivrea, A.S.L. TO4, Dept. of Radiotherapy, Ivrea, Italy, ³Istituto di Candiolo-Fondazione del Piemonte per l’Oncologia IRCCS, Dept. of Radiotherapy, Turin, Italy, ⁴Istituto Nazionale dei Tumori Regina Elena, Dept. of Radiotherapy, Rome, Italy, ⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Dept. of Radiotherapy, Milan, Italy, ⁶Cliniche Gavazzeni-Humanitas GAV, Dept. of Radiotherapy, Bergamo, Italy, ⁷Ospedale degli Infermi, Dept. of Radiotherapy, Biella, Italy, ⁸Compreseorio Sanitario di Bolzano, Dept. of Radiotherapy, Bolzano, Italy, ⁹Azienda Ospedaliero Universitaria S. Maria della Misericordia, Dept. of Radiotherapy, Udine, Italy, ¹⁰IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ¹¹IRCCS Ospedale San Raffaele, Dept. of Urology, Milan, Italy

Aims and objectives of this presentation

The efficacy and feasibility of radiation therapy to the primary tumor in patients with metastatic castration resistant prostate cancer

By: Fujita N.¹, Momota M.¹, Tobisawa Y.¹, Yoneyama T.¹, Yamamoto H.¹, Imai A.¹, Hatakeyama S.¹, Ito H.², Yoneyama T.¹, Hashimoto Y.¹, Yoshikawa K.³, Ohyama C.¹

¹Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, ²Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, ³Mutsu General Hospital, Dept. of Urology, Mutsu, Japan

Aims and objectives of this presentation

External beam radiotherapy (EBRT) compared with EBRT plus HDR brachytherapy boost (EBRT+BRACHY) dose escalation for intermediate- or high-risk prostate cancer: Higher disease control and survival with lower distant metastases and toxicity


IMOR Foundation, Medical Institute for Onco-Radiotherapy, Dept. of Radiation Oncology,
Assessing the impact and predictors of other-cause mortality in patients treated with post-prostatectomy salvage radiation therapy in order to avoid possible overtreatment: Results from a large, multi-institutional study

By: Mazzone E.¹, Fossati N.¹, Karnes R.J.², Boorjian S.A.², Luca B.², Bossi A.³, Di Muzio N.⁴, Cozzarini C.⁴, Noris Chiorda B.⁴, Gandaglia G.¹, Scuderì S.¹, Bartkowiak D.⁵, Böhmer D.⁶, Shariat S.⁷, Goldner G.⁶, Battaglia A.⁹, Joniau S.⁹, Haustermans K.¹⁰, De Meerleer G.¹⁰, Fonteyne V.¹¹, Ost P.¹¹, Van Poppel H.⁹, Montorsi F.¹, Wiegel T.⁵, Briganti A.¹

¹IRCCS Ospedale San Raffaele, Division of Oncology, Unit of Urology; URI, Milan, Italy,
²Mayo Clinic, Dept. of Urology, Rochester, United States of America,
³Gustave Roussy Institute, Dept. of Radiation Oncology, Villejuif, France,
⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy,
⁵University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany,
⁶Charité University Hospital Berlin, Dept. of Radiation Oncology, Berlin, Germany,
⁷Medical University of Vienna, Dept. of Urology, Vienna, Austria,
⁸Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria,
⁹University Hospitals Leuven, Dept. of Urology, Leuven, Belgium,
¹⁰University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium,
¹¹Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

Clinical result of helical tomotherapy for high-risk and very high-risk prostate cancer at single institution

By: Tsukuda F.¹, Horiguchi Y.², Ogata A.¹, Sakamoto N.², Koga S.¹, Hama Y.³

¹Edogawa Hospital, Transplantation and Regenerative Medicine Center, Dept. of Urology, Tokyo, Japan,
²Edogawa Hospital, Dept. of Urology, Tokyo, Japan,
³Edogawa Hospital, Tokyo Edogawa Cancer Center, Dept. of Radiology, Tokyo, Japan

Comparison of the oncologic outcomes of men with high risk prostate cancer treated with either I-125 or Pd-103 brachytherapy

By: Skouteris V.¹, Stock R.², Dounis A.¹, Koutsouveli E.¹, Katsochi D.¹, Kollias G.¹, Skouteris M.¹, Metsinis M.¹, Stone N.³

¹Hygeia Brachytherapy Center, Dept. of Urology, Athens, Greece,
²The Icahn School of Medicine at Mount Sinai, Dept. of Radiation Oncology, New York, United States of America,
³The Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America
Aims and objectives of this presentation
722

**723**

**Persistent under-utilization of adjuvant radiotherapy in patients with adverse pathological features at radical prostatectomy: A national cancer database (NCDB) analysis**

By: **Rakic N. 1**, Fotouhi A. 2, Baumgarten L. 1, Borchert A. 1, Dalela D. 1, Sood A. 1, Arora S. 1, Menon M. 1, Abdollah F. 1

1Henry Ford Hospital, Vattikutti Urology Institute, Detroit, United States of America,
2Wayne State University, School of Medicine, Detroit, United States of America

Aims and objectives of this presentation
723

**724**

**Identification of differentially expressed genes to predict radioresistant prostate carcinomas**

By: **Nestler T. 1**, Wittersheim M. 2, Hellmich M. 3, Pfister D. 1, Odenthal M. 2, Büttner R. 2, Schäfer S. 2, Heidenreich A. 1

1University Hospital of Cologne, Dept. of Urology and Uro-Oncology, Cologne, Germany,
2University Hospital of Cologne, Institute of Pathology, Cologne, Germany,
3University of Cologne, Institute of Medical Statistics and Computational Biology, Cologne, Germany

Aims and objectives of this presentation
724

**725**

**Biochemical control of a combination of cyclooxygenase-2 inhibitor and 125I-brachytherapy in an open-labeled controlled randomized trial as a secondary endpoint**

By: **Nakai Y. 1**, Tanaka N. 1, Miyake M. 1, Anai S. 1, Asakawa I. 2, Yamaki K. 2, Hasegawa M. 2, Fuji T. 3, Fujimoto K. 1

1Nara Medical University, Dept. of Urology, Kashihara, Japan,
2Nara Medical University, Dept. of Radiation Oncology, Kashihara, Japan,
3Nara Medical University, Dept. of Pathology, Kashihara, Japan

Aims and objectives of this presentation
725

**726**

**Comparison of the morbidity in men with intermediate and high-risk prostate cancer treated with either I-125 or Pd-103 brachytherapy combined with external beam irradiation**

By: **Stone N. 1**, Skouteris V. 2, Dounis A. 2, Koutsouveli E. 3, Katsochi D. 3, Kollias G. 3, Skouteris M. 2, Metsinis M. 2, Stock R. 4

1The Icahn School of Medicine at Mount Sinai, Dept. of Urology, New York, United States of America,
2Hygeia Brachytherapy Center, Dept. of Urology, Athens, Greece,
3Hygeia Brachytherapy Center, Dept. of Radiation Oncology, Athens, Greece,
4The Icahn School
High detection rate of colorectal cancer in scheduled serial total colonoscopy screening after radiation therapy for prostate cancer

By: Nakamura Y., Kageyama Y., Soma T., Aoki Y., Fukui N., Sakai Y.
Saitama Cancer Center, Dept. of Urology, Saitama, Japan

Is external beam radiotherapy for prostate cancer a risk factor for bladder or rectal cancer?

By: Mekayten M.1, Duvdevani M.1, Yutkin V.1, Pode D.1, Hidas G.1, Landau E.H.1, Youssef F.1, Cohn Y.1, Gielchinsky I.1, Lorber A.1, Sapir E.2, Meirovitz A.2, Gofrit O.N.1, Wygoda M.2
1Hadassah Hebrew University Medical Center, Dept. of Urology, Jerusalem, Israel, 2Hadassah Hebrew University Medical Center, Dept. of Oncology, Jerusalem, Israel

Prostate cancer as a risk factor for bladder carcinoma

By: Rinott Mizrahi G., Friedman B., Boyarsky L., Rani Z., Orlin I., Yasinov F., Fares G., Stein A., Dekel Y.
Carmel Medical Center, Dept. of Urology, Haifa, Israel